TB Market Access Research

Featured Research

Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines

Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

Budgetary impact of using BPaL for treating extensively drugresistant tuberculosis

BPaL Research: A Snapshot

Update on Pretomanid, in Combination with Bedaquiline and Linezolid (the BPaL Regimen) in Drug-Resistant TB

Access to the latest treatment innovations is a human right.

3,611 patients in more than 33 countries accessed TB Alliance products for highly drug-resistant TB alone in 2021. We cannot afford to stop until our treatments are available to everyone who needs them.

4986 patients
in 41 countries




TB Market Research

Determining the Pediatric TB Burden

A major historical challenge in tackling childhood TB has been understanding the scope of the problem.

Learn More

The Global TB Market

Pathway to Patients: Charting the Dynamics of the Global TB Drug Market, was the first comprehensive analysis of how today's TB drugs reach patients on a global scale.

Learn More

Value Propositions of New Regimens

TB Alliance sought opinions on attributes that key decision-makers want in new regimens, including safety, efficacy, drug delivery, side effect profiles, and cost.

Learn More

Understanding Regimen Change

TB Alliance investigated health systems to understand the regimen change process, in order to accelerate and maximize the uptake of new products.

Learn More

Defining the Role of the Private Sector in Treatment

TB treatment is widely understood to be a public sector responsibility. However, our research found that in some countries the volume of TB drugs sold in the private sector is equal to or greater than the volume sold in the public sector.

Learn More